At the Capital Markets Event, Cicor will provide insights into its growth strategy, value creation through acquisitions, the contribution of operational excellence to achieving its mid-term targets and the strategic partnership with Clayens. The following financial mid-term targets will be presented today:
• Annual organic growth of 7-10%
• Sales of >CHF 600 million within 3 – 4 years
• Profitability of 7-10% (core EBIT) and 10-13% (EBITDA)
• Core return on invested capital (core ROIC) of >15%
• Debt leverage (net debt / EBITDA ratio) of <2.75
• Capital expenditure (CAPEX) of less than 3% of sales
Cicor is very well positioned. The company is benefiting from dynamic development in its focus markets of industry, medical technology, and aerospace and defence. Acquisitions will continue to play an important role in Cicor’s strategy, as the company sees attractive opportunities in a highly fragmented market. The current mid-term guidance includes some moderate level of acquisitions. The effective level of inorganic growth may lead to revised financial mid-term targets. The payment of a dividend will be considered as soon as Cicor achieves a sustainable positive net cash flow.
The existing guidance for the current financial is confirmed: For 2023, Cicor expects sales of CHF 380-410 million and an operating result (EBITDA) of CHF 40-45 million.
All presentations from today’s Capital Markets Event are available on Cicor’s website. |
